Clinical Trial Update: Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed plus bevacizumab in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: COMPLETED